Imagine a blood vessel that starts to bulge like a weak spot on a garden hose. Usually, doctors can only fix these when they are already huge and about to burst. This new device acts like a supportive sleeve that stops the bulge from growing in the first place, long before it becomes a crisis.
90% of abdominal aortic aneurysm patients are diagnosed at an early stage where no treatment exists, leaving them to wait until the condition becomes critical and high-risk.
A nitinol-based, non-active Class III aortic implant delivered via catheter to stabilize small aneurysms.
If you are a manufacturer dealing with a lack of options for early-stage patients — this project developed a nitinol-based implant that stabilizes small aneurysms. It opens a new market for patients with 3-5 cm diameters who currently have no therapy.
If you are a clinic dealing with high-risk late-stage surgeries — this project developed a minimally-invasive catheter-based tool. It allows you to treat patients earlier, reducing the need for costly and risky interventions later.
If you are an insurer dealing with the high cost of emergency rupture treatments — this project developed a size-stabilizing treatment for small AAAs. This prevents the 80% mortality rate associated with ruptures and lowers long-term care costs.
Based on available project data, the specific unit price or cost of the device is not disclosed.
The project is currently finishing R&D activities to prepare for the first-in-human study and seeking CE mark regulatory clearance.
The solution is described as patent-protected and based on discoveries made at Stanford University.
The device is classified as a class III non-active aortic implant and is pursuing a CE mark for regulatory clearance.
The project period runs from 2024-01-01 to 2025-12-31, with commercialization planned to follow the grant and investment components.
The project is led by a single SME, Angiolutions GmbH from Germany, with a 100% industry ratio. This lean structure suggests a fast-track approach to commercialization, utilizing a combination of grant and investment funding to move from R&D to market.
Contact Angiolutions GmbH in Germany for partnership or licensing inquiries.
Contact us to explore licensing opportunities for this Class III medical device.
